Search ASX code:
Generic filters

Search ASX code:
Generic filters

Search ASX code:
Generic filters

Search ASX code:
Generic filters

Cochlear (ASX:COH) share price on watch, weak trading revealed

The Cochlear (ASX: COH) share price is on watch this morning after the hearing aid business announced a trading update.

What is Cochlear?

Cochlear is one of the world’s leading medical businesses. Cochlear designs, manufactures and supplies the Nucleus cochlear implant, the Hybrid electro-acoustic implant and the Baha bone conduction implant. Graeme Clark invented the first device in 1982, allowing first-user Graham Carrick to hear for the first time for 17 years. Some of the most recent modifications allow users to play sound from their phone directly into their implant.

Cochlear’s update

Cochlear said that there has been a “significant” decline in surgeries across major markets. The company was expecting this decline.

Sales revenue across the business dropped around 60% in April 2020 with cochlear and acoustic implants most severely affected. Cochlear implant unit sales declined by approximately 80% across developed countries with most elective surgeries cancelled in US and Western Europe.

The market was expecting this, it’s why the Cochlear share price is down 28% from 19 February 2020.

Thankfully, Chinese surgeries recommenced in late February and continued to recover throughout April. Surgeries are now running close to pre-coronavirus run rates.

Cochlear’s Services business, which represents around 30% of regular revenue has also been hurt with April sales dropping by 30%.

The company’s remote servicing capability, including Cochlear Link and Remote Check, are assisting clinicians and recipients.

What’s Cochlear doing?

It has significantly reduced non-essential spending and capital expenditure until there is a sustained increase in surgeries. It has frozen hiring and implemented temporary pay reductions for leadership.

Cochlear is still investing in R&D and its liquidity has been strengthened with a $1.1 billion capital raising and $225 million increase in debt facilities.

Is the Cochlear share price a buy?

With economies starting to open again, it seems Cochlear may have already faced the worst of it. It’s going to take time for life to get back to normal, but a second wave could cause more restrictions on surgeries.

It could be a better idea to buy these technology shares instead which are less affected:

Disclosure: at the time of publishing, Jaz does not have a financial interest in any of the companies mentioned.

Are you stuck wondering where to invest right now? Have you got cash 'sitting on the sidelines'? Are you looking for dividend income AND growth but don't know where to start? Rask's expert ASX analyst team has just released a full report, detailing where we'd invest $10,000 right now.

Not only are we offering these 11 investment ideas completely FREE, we've also released an in-depth podcast to go with the report!

So, whether you have $2,000 or $50,000, our brand new analyst report could help transform your watchlist. Right now, you can get the full analyst report emailed to you for FREE by CLICKING HERE NOW or simply entering your email below.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Are you stuck wondering where to invest right now? Have you got cash 'sitting on the sidelines'? Are you looking for dividend income AND growth but don't know where to start? Rask's expert ASX analyst team has just released a full report, detailing where we'd invest $10,000 right now.

Not only are we offering these 11 investment ideas completely FREE, we've also released an in-depth podcast to go with the report!

So, whether you have $2,000 or $50,000, our brand new analyst report could help transform your watchlist. Right now, you can get the full analyst report emailed to you for FREE by CLICKING HERE NOW.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

LIVE ASX Chat - Join in!

Play Video

Keep reading:

Rask Analyst’s $10,000 Hypothetical Portfolio 

Rask Australia’s expert analysts have just released 11 stock & ETF positions they’d buy right now as part of a $10,000 hypothetical portfolio. 

Completely free, this report comes with the exact ticker codes, how much the analysts would invest and a detailed over the company and why we like it. Plus a 60-min podcast! 

Simply enter your email address and we’ll send you the report.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.